Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis
暂无分享,去创建一个
T. Griffin | A. Martini | J. Lipton | R. Cron | A. Horne | P. Picco | N. Ruperto | M. Jeng | N. Ayaz | E. Demirkaya | J. Akikusa | T. Hennon | F. Bovis | P. Barone | K. Stine | S. Al‐Mayouf | A. Ravelli | H. Tezer | L. Breda | I. Bolt | G. Horneff | O. Vougiouka | J. de Inocencio | C. D. De Cunto | A. Buoncompagni | C. Magalhaes | B. Lattanzi | F. Minoia | R. Gallizzi | S. Davì | L. Weaver | W. Sewairi | M. Ioseliani | S. Enciso | S. Magni Manzoni | I. Rumba-Rozenfelde | Z. Dāvidsone | Z. Davidsone | B. Bica | Ageza M Kapovic
[1] C. Wouters,et al. Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients , 2014, Arthritis & rheumatology.
[2] N. Wulffraat,et al. Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis , 2014, Arthritis & rheumatology.
[3] R. Cron,et al. Genetic Defects in Cytolysis in Macrophage Activation Syndrome , 2014, Current Rheumatology Reports.
[4] R. Cron,et al. Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome , 2013, The Journal of Rheumatology.
[5] R. Cron,et al. Intensive care requirement, rather than degree of serum ferritin elevation, predicts mortality in macrophage activation syndrome. , 2012, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[6] T. Brogan,et al. Intensive care requirement, rather than degree of serum ferritin elevation, predicts mortality in macrophage activation syndrome , 2012 .
[7] Sebastian F N Bode,et al. Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis , 2012, Arthritis Research & Therapy.
[8] R. Cron,et al. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment , 2012, Genes and Immunity.
[9] G. Koretzky,et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. , 2011, The Journal of clinical investigation.
[10] R. Cron,et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. , 2011, Rheumatology.
[11] E. Mellins,et al. Macrophage activation syndrome: advances towards understanding pathogenesis , 2010, Current opinion in rheumatology.
[12] Y. Troyanov,et al. Macrophage Activation Syndrome Treated with Anakinra , 2010, The Journal of Rheumatology.
[13] A. Ramanan,et al. A case of macrophage activation syndrome successfully treated with anakinra , 2008, Nature Clinical Practice Rheumatology.
[14] R. Cron,et al. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. , 2007, The Journal of rheumatology.
[15] A. Ramanan,et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. , 2007, Arthritis and rheumatism.
[16] M. Aricò,et al. HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis , 2007, Pediatric blood & cancer.
[17] A. Martini,et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. , 2005, The Journal of pediatrics.
[18] M. Suarez‐Almazor,et al. International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 , 2004 .
[19] R. Schneider,et al. Macrophage activation syndrome: What's in a name! , 2003 .
[20] R. Egeler,et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. , 2002, Blood.
[21] B. Athreya. Is macrophage activation syndrome a new entity? , 2002, Clinical and experimental rheumatology.
[22] S. Sawhney,et al. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders , 2001, Archives of disease in childhood.
[23] E. Haddad,et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. , 1996, The Journal of pediatrics.
[24] A. Fischer,et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. , 1996, Leukemia.
[25] A. Martini,et al. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. , 1996, The Journal of pediatrics.
[26] Mina L. Xu,et al. Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. , 2014, American journal of clinical pathology.
[27] A. Martini,et al. Toward the Development of New Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis , 2012 .
[28] M. Laposata. SI unit conversion guide , 1992 .